Overview
- Phase 3 RASolute 302 results published May 31 showed median overall survival of 13.2 months for daraxonrasib versus about 6.6–6.7 months for chemotherapy and a hazard ratio near 0.40 indicating roughly a 60% relative reduction in the risk of death.
- Daraxonrasib is an oral RAS(ON) inhibitor that binds mutant KRAS common to more than 90% of pancreatic tumors using a molecular‑glue mechanism that blocks the driver mutation long considered hard to target.
- The FDA has opened an expanded access pathway and signaled an expedited review, and Revolution Medicines is moving toward an accelerated filing while clinics report heavy demand from eligible patients.
- Trial data showed different side effects than chemotherapy with common toxicities including rash and mucosal sores, lower rates of severe adverse events on the drug (43.6% vs 57.5%) and far fewer treatment discontinuations (1.2% vs 11.2%).
- Coverage has sometimes conflated median survival time with survival rates or absolute death risk, prompting clinicians to correct the record and to stress clear statistical framing and further biomarker and resistance studies before broad changes to care are adopted.